New RSV treatment, Nirsevimab, reduces hospitalizations by 83% in infants - breakthrough study reveals. Major advances in treating respiratory syncytial virus (RSV) have emerged, including a vaccine for pregnant mothers and a drug treatment for babies under one year. Nirsevimab was found to be 83% effective in preventing hospitalizations and 75% effective in reducing severe RSV in infants. However, demand for the drug has surpassed supply, leading to CDC recommendations to restrict its use to high-risk babies. Supplies are expected to gradually increase in the coming months.
Discover a breakthrough study that identifies Alzheimer's risk before symptoms, paving the way for new treatments. A game-changer in Alzheimer's research!
Discover a breakthrough study that identifies Alzheimer's risk before symptoms, paving the way for new treatments. A game-changer in Alzheimer's research!